Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy

References

• Garg AD, Dudek-Peric AM, Romano E, et al. Immunogenic cell death. Int J Dev Biol. 2015;59:131–140.
   PubMed Web of Science ®Google Scholar
• Garg AD, Nowis D, Golab J, et al. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Bba-Rev Cancer. 2010;1805:53–71.
   PubMed Web of Science ®Google Scholar
• Chaput N, De botton S, Obeid M, et al. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med. 2007;85(10):1069–1076.
   PubMed Web of Science ®Google Scholar
• Kepp O, Tesniere A, Zitvogel L, et al. The immunogenicity of tumor cell death. Curr Opin Oncol. 2009;211:71–76.
   Web of Science ®Google Scholar
• Kepp O, Tesniere A, Schlemmer F, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009;14:364–375.
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014;3:e955691.
   PubMed Web of Science ®Google Scholar
• Dudek AM, Garg AD, Krysko DV, et al. Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev. 2013;24:319–333.
   PubMed Web of Science ®Google Scholar
• Kepp O, Semeraro M, Bravo-San Pedro JM, et al. Eif2 alpha phosphorylation as a biomarker of immunogenic cell death. Sem Cancer Biol. 2015;33:86–92.
   PubMed Web of Science ®Google Scholar
• Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014;21:39–49.
   PubMed Web of Science ®Google Scholar
• Kepp O, Menger L, Vacchelli E, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev. 2013;24:311–318.
   PubMed Web of Science ®Google Scholar
• Menger L, Vacchelli E, Adjemian S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med. 2012;4:143–199.
   Web of Science ®Google Scholar
• Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of damps in immunogenic cell death. Front Immunol. 2015;6:588.
   PubMed Web of Science ®Google Scholar
• Adkins I, Fucikova J, Garg AD, et al. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology. 2014;3:12.
   Web of Science ®Google Scholar
• Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011;153:198–205.
   PubMed Web of Science ®Google Scholar
• Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev. 2013;65:1880–1895.
   PubMed Web of Science ®Google Scholar
• Orive G, Anitua E, Pedraz JL, et al. Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci. 2009;10:682–692.
   PubMed Web of Science ®Google Scholar
• Maeda H, Matsumura Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy preface. Adv Drug Deliv Rev. 2011;63:129–130.
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136–151.
   PubMed Web of Science ®Google Scholar
• Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev. 2011;63:640–658.
   PubMed Web of Science ®Google Scholar
• Hak S, Reitan NK, Haraldseth O, et al. Intravital microscopy in window chambers: a unique tool to study tumor angiogenesis and delivery of nanoparticles. Angiogenesis. 2010;13:113–130.
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161:175–187.
   PubMed Web of Science ®Google Scholar
• Iyer AK, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11:812–818.
   PubMed Web of Science ®Google Scholar
• Nichols JW, Bae YH. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012;7:606–618.
   PubMed Web of Science ®Google Scholar
• Yamashita F, Hashida M. Pharmacokinetic considerations for targeted drug delivery. Adv Drug Deliv Rev. 2013;65:139–147.
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148:135–146.
   PubMed Web of Science ®Google Scholar
• Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71–79.
   PubMed Web of Science ®Google Scholar
• Gubernator J. Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv. 2011;8:565–580.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil® - The first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–134.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Grenader T. Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. Eur J Pharmaceut Sci. 2012;45:388–398.
   PubMed Web of Science ®Google Scholar
• Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68:701–787.
   PubMed Web of Science ®Google Scholar
• Drummond DC, Meyer O, Hong KL, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691–743.
   PubMed Web of Science ®Google Scholar
• Charrois GJR, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta Biomembr. 2004;1663:167–177.
   PubMed Web of Science ®Google Scholar
• Seynhaeve ALB, Dicheva BM, Hoving S, et al. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: Evaluated by in vitro/in vivo live cell imaging. J Control Release. 2013;172:330–340.
   PubMed Web of Science ®Google Scholar
• Perez-Herrero E, Fernandez-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.
   PubMed Web of Science ®Google Scholar
• Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Canc Res. 2007;13:2722–2727.
   PubMed Web of Science ®Google Scholar
• Li L, Ten Hagen TLM, Schipper D, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release. 2010;143:274–279.
   PubMed Web of Science ®Google Scholar
• Dos Santos N, Waterhouse D, Masin D, et al. Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity. J Control Release. 2005;105:89–105.
   PubMed Web of Science ®Google Scholar
• Gubernator J, Chwastek G, Korycinska M, et al. The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures improved drug retention in vitro and in vivo. J Control Release. 2010;146:68–75.
   PubMed Web of Science ®Google Scholar
• Lu T, Lokerse WJM, Seynhaeve ALB, et al. Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response. J Control Release. 2015;220:425–437.
   PubMed Web of Science ®Google Scholar
• Zhang QL, Ding JX, Lv CW, et al. Epirubicin-complexed polypeptide micelle effectively and safely treats hepatocellular carcinoma. Polymers. 2015;7:2410–2430.
   Web of Science ®Google Scholar
• Kim KS, Hong SW, Kim H, et al. Hyaluronate-Flt1 peptide conjugate/epirubicin micelles for theranostic application to liver cancers. Rsc Advances. 2015;5:48615–48618.
   Web of Science ®Google Scholar
• Angelova N, Yordanov G. Nanoparticles of poly(styrene-co-maleic acid) as colloidal carriers for the anticancer drug epirubicin. Colloid Surface Physicochem Eng Aspect. 2014;452:73–81.
   Web of Science ®Google Scholar
• Di-Wen S, Pan GZ, Hao L, et al. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers. Int J Pharm. 2016;500:54–61.
   PubMed Web of Science ®Google Scholar
• Gubernator J, Lipka D, Korycinska M, et al. Efficient human breast cancer xenograft regression after a single treatment with a novel liposomal formulation of epirubicin prepared using the EDTA ion gradient method. Plos One. 2014;9:e91487.
   PubMed Web of Science ®Google Scholar
• Lipka D, Gubernator J, Filipczak N, et al. Vitamin C-driven epirubicin loading into liposomes. Int J Nanomedicine. 2013;8:3573–3585.
   PubMedGoogle Scholar
• Zhao YZ, Dai DD, Lu CT, et al. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Cancer Lett. 2013;330:74–83.
   PubMed Web of Science ®Google Scholar
• Li CL, Cui JX, Wang CX, et al. Lipid composition and grafted peg affect in vivo activity of liposomal mitoxantrone. Int J Pharm. 2008;362:60–66.
   PubMed Web of Science ®Google Scholar
• Li CL, Cui JX, Wang CX, et al. Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm. 2008;70:657–665.
   PubMed Web of Science ®Google Scholar
• Pedrosa LRC, Van Tellingen O, Soullie T, et al. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model. Eur J Pharm Biopharm. 2015;94:207–219.
   PubMed Web of Science ®Google Scholar
• Bugaut H, Bruchard M, Berger H, et al. Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells. Plos One. 2013;8:e65181.
   PubMed Web of Science ®Google Scholar
• Alomrani AH, El Maghraby GM, Alanazi FK, et al. Liposomes for enhanced cytotoxic activity of bleomycin. Drug Dev Res. 2011;72:265–273.
   Web of Science ®Google Scholar
• Arndt D, Zeisig R, Bechtel D, et al. Liposomal bleomycin: increased therapeutic activity and decreased pulmonary toxicity in mice. Drug Deliv. 2001;8:1–7.
   PubMed Web of Science ®Google Scholar
• Kullberg M, Mann K, Anchordoquy TJ. Targeting her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. Mol Pharm. 2012;9:2000–2008.
   PubMed Web of Science ®Google Scholar
• Koshkaryev A, Piroyan A, Torchilin VP. Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. Cancer Lett. 2013;334:293–301.
   PubMed Web of Science ®Google Scholar
• Ashley JD, Stefanick JF, Schroeder VA, et al. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo. J Med Chem. 2014;57:5282–5292.
   PubMed Web of Science ®Google Scholar
• Zuccari G, Milelli A, Pastorino F, et al. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. J Control Release. 2015;211:44–52.
   PubMed Web of Science ®Google Scholar
• Yang XJ, Pang JX, Shen N, et al. Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. Oncotarget. 2016;7:363:82-94.
   Web of Science ®Google Scholar
• Shen S, Du XJ, Liu J, et al. Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy. J Control Release. 2015;208:14–24.
   PubMed Web of Science ®Google Scholar
• Menger L, Vacchelli E, Kepp O, et al. Trial watch Cardiac glycosides and cancer therapy. Oncoimmunology. 2013;2:e23082.
   PubMed Web of Science ®Google Scholar
• Guzmán M, Sellés E, Aberturas MC. Effect of human-plasma on the stability of large multilamellar liposomes with digitoxin. Drug Dev Ind Pharm. 1989;15:387–399.
   Web of Science ®Google Scholar
• Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nature Rev Clin Oncol. 2009;6:638–647.
   PubMed Web of Science ®Google Scholar
• Doloff JC, Chen CS, Waxman DJ. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol Canc. 2014;13:158.
   PubMed Web of Science ®Google Scholar
• Abdella EM. Short-term comparative study of the cyclophosphamide genotoxicity administered free and liposome-encapsulated in mice. Iran J Cancer Prev. 2012;5:51–60.
   PubMedGoogle Scholar
• Tohamy AA, Azeem AAA, Shafaa MW, et al. Alleviation of genotoxic effects of cyclophosphamide using encapsulation into liposomes in the absence or presence of vitamin C. Gen Physiol Biophys. 2012;31:85–91.
   PubMed Web of Science ®Google Scholar
• Zalba S, Navarro I, Trocóniz IF, et al. Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo. Eur J Pharm Biopharm. 2012;81:273–280.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takizawa T, Kuwata Y, et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm. 2008;346:143–150.
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Doi Y, Nakamura K, et al. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J Control Release. 2010;142:167–173.
   PubMed Web of Science ®Google Scholar
• Wang K, Liu L, Zhang T, et al. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer. Int J Nanomedicine. 2011;6:3207–3218.
   PubMed Web of Science ®Google Scholar
• Yang LX, Xiao HH, Yan LS, et al. Lactose targeting oxaliplatin prodrug loaded micelles for more effective chemotherapy of hepatocellular carcinoma. J Mater Chem B. 2014;2:2097–2106.
   PubMed Web of Science ®Google Scholar
• Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–2681.
   PubMed Web of Science ®Google Scholar
• Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 2014;9:467–483.
   PubMed Web of Science ®Google Scholar
• Balasubramanian SV, Straubinger RM. taxol-lipid interactions - taxol-dependent effects on the physical-properties of model membranes. Biochemistry. 1994;33:8941–8947.
   PubMed Web of Science ®Google Scholar
• Koudelka S, Turánek J. Liposomal paclitaxel formulations. J Control Release. 2012;163:322–334.
   PubMed Web of Science ®Google Scholar
• Crosasso P, Ceruti M, Brusa P, et al. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release. 2000;63:19–30.
   PubMed Web of Science ®Google Scholar
• Yoshizawa Y, Kono Y, Ogawara K, et al. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm. 2011;412:132–141.
   PubMed Web of Science ®Google Scholar
• Fumoleau P, Coudert B, Isambert N, et al. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007;18:9–15.
   PubMed Web of Science ®Google Scholar
• Scherzinger-Laude K, Schonherr C, Lewrick F, et al. Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906). Int J Nanomedicine. 2013;8:2197–2211.
   PubMed Web of Science ®Google Scholar
• Sukkurwala AQ, Adjemian S, Senovilla L, et al. Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology. 2014;3:e28473.
   PubMed Web of Science ®Google Scholar
• Acton EM, Ryan KJ, Luetzow AE. anti-tumor septacidin analogs. J Med Chem. 1977;20:1362–1371.
   PubMed Web of Science ®Google Scholar
• Kontogiannopoulos KN, Assimopoulou AN, Dimas K, et al. Shikonin-loaded liposomes as a new drug delivery system: physicochemical characterization and in vitro cytotoxicity. Eur J Lipid Sci Tech. 2011;113:1113–1123.
   Web of Science ®Google Scholar
• Kontogiannopoulos KN, Assimopoulou AN, Hatziantoniou S, et al. Papageorgiou VP: chimeric advanced drug delivery nano systems (chi-aDDnSs) for shikonin combining dendritic and liposomal technology. Int J Pharm. 2012;422:381–389.
   PubMed Web of Science ®Google Scholar
• Xia HM, Tang CY, Gui H, et al. Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo. Biosci Rep. 2013;33:207–215.
   Web of Science ®Google Scholar
• Matthaiou EI, Barar J, Sandaltzopoulos R, et al. Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. Int J Nanomedicine. 2014;9:1855–1870.
   PubMed Web of Science ®Google Scholar
• Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Canc. 2006;95:S2–S6.
   Web of Science ®Google Scholar
• Denis I, El Bahhaj F, Collette F, et al. Vorinostat-polymer conjugate nanoparticles for acid-responsive delivery and passive tumor targeting. Biomacromolecules. 2014;15:4534–4543.
   PubMed Web of Science ®Google Scholar
• Tran TH, Choi JY, Ramasamy T, et al. Hyaluronic acid-coated solid lipid nanoparticles for targeted delivery of vorinostat to CD44 overexpressing cancer cells. Carbohydr Polymer. 2014;114:407–415.
   PubMed Web of Science ®Google Scholar
• Mohamed EA, Zhao YQ, Meshali MM, et al. Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)-b-poly(dl-lactic acid) micelle nanocarriers: characterization and effects on pharmacokinetics in rat serum and urine. J Pharm Sci. 2012;101:3787–3798.
   PubMed Web of Science ®Google Scholar
• Kwak TW, Kim DH, Jeong YI, et al. Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells. J Nanobiotechnology. 2015;13. DOI:10.1186/s12951-015-0122-4
   PubMed Web of Science ®Google Scholar
• Yang Y, Li XJ, Chen Z, et al. Wogonin Induced calreticulin/annexin A1 exposure dictates the immunogenicity of cancer cells in a PERK/AKT dependent manner. Plos One. 2012;7:e50811.
   PubMed Web of Science ®Google Scholar
• Cheng J, Cheng L, Chen BA, et al. Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line. Int J Nanomedicine. 2012;7:2843–2852.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang HJ, Chen BA, et al. Effect of magnetic nanoparticles on apoptosis and cell cycle induced by wogonin in Raji cells. Int J Nanomedicine. 2012;7:789–798.
   PubMed Web of Science ®Google Scholar
• Wehbe M, Chernov L, Chen K, et al. PRCosomes: pretty reactive complexes formed in liposomes. J Drug Target. 2016:1–10.
   Web of Science ®Google Scholar
• Gang W, Jie WJ, Ping ZL, et al. Liposomal quercetin: evaluating drug delivery in vitro and biodistribution in vivo. Expet Opin Drug Deliv. 2012;9:599–613.
   PubMed Web of Science ®Google Scholar
• Yuan ZP, Chen LJ, Fan LY, et al. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clin Canc Res. 2006;12:3193–3199.
   PubMed Web of Science ®Google Scholar
• Song YZ, Huang ZJ, Song Y, et al. The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient. Int J Nanomedicine. 2014;9:3611–3621.
   PubMed Web of Science ®Google Scholar
• Li M, Liu Y, Feng L, et al. Polymeric complex micelles with double drug-loading strategies for folate-mediated paclitaxel delivery. Colloids Surf B Biointerfaces. 2015;131:191–201.
   PubMed Web of Science ®Google Scholar
• Tagami T, May JP, Ernsting MJ, et al. A thermosensitive liposome prepared with a <sup>Cu²⁺ gradient demonstrates improved pharmacokinetics, drug delivery and antitumor efficacy. J Control Release. 2012;161:142–149.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229.
   PubMed Web of Science ®Google Scholar
• Garg AD, De Ruysscher D, Agostinis P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis. Oncoimmunology. 2016;5(2):1–17.
   Web of Science ®Google Scholar
• Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–465.
   PubMed Web of Science ®Google Scholar
• Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol. 2009;16:91–99.
   Web of Science ®Google Scholar
• Ishida T, Maeda R, Ichihara M, et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release. 2003;88:35–42.
   PubMed Web of Science ®Google Scholar
• Barenholz JYC. Adverse immune effects of liposomes: Complement activation, immunogenicity and immune suppression. In: Peer D, editor. Chapter 12. Harnessing biomaterials for nanomedicine: Preparation, toxicity and applications. Singapore: Pan Stanford Publishing Pte Ltd; 2009. p. 1–19.
   Google Scholar
• Verhoef JJF, Anchordoquy TJ. Questioning the use of PEGylation for drug delivery. Drug Deliv Transl Res. 2013;3:499–503.
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Nawata K, Shimizu T, et al. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int J Pharm. 2013;456:235–242.
   PubMed Web of Science ®Google Scholar
• Cicchelero L, Denies S, Devriendt B, et al. Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells? Oncoimmunology. 2015;4(12):e1048413-1-e1048413-9.
   Web of Science ®Google Scholar
• Ji J, Zhang YF, Chen WR, et al. Dc vaccine generated by ala-pdt-induced immunogenic apoptotic cells for skin squamous cell carcinoma. Oncoimmunology. 2016;5(6):e1072674-1-e1072674-2.
   Web of Science ®Google Scholar
• Van Broekhoven CL, Parish CR, Demangel C, et al. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 2004;64:4357–4365.
   PubMed Web of Science ®Google Scholar
• Bezu L, Gomes-de-Silva LC, Dewitte H, et al. Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015;6:187.
   PubMed Web of Science ®Google Scholar
• Kato C, Kajiwara T, Numazaki M, et al. Oligomannose-coated liposomes activate erk via src kinases and pi3k/akt in j774a.1 cells. Biochem Biophys Res Commun. 2008;372:898–901.
   PubMed Web of Science ®Google Scholar
• Gerber HP, Sapra P, Loganzo F, et al. Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect? Biochem Pharmacol. 2016;102:1–6.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Muehlmann LA, Joanitti GA, Silva JR, et al. Liposomal photosensitizers: potential platforms for anticancer photodynamic therapy. Braz J Med Biol Res. 2011;44:729–737.
   PubMed Web of Science ®Google Scholar